Anle138b

Anle138b is an oligomeric aggregation inhibitor that prevents the formation of pathological prion protein (PrPSc) and α-synuclein aggregates. It exhibits neuroprotective effects in Parkinson’s disease models and improves motor performance in α-synucleinopathy models. Anle138b is a promising therapeutic candidate for neurodegenerative diseases characterized by protein misfolding and aggregation, including prion diseases and synucleinopathies.

Classification: Warning. Hazard Statements

H315 - H319 - H335

Precautionary Statements

P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338

Anle138b (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-607)

Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.

• Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
• Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
• Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
• QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
• Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity

To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).

Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).